I see Roger Aston resigned from IDT, saying he would now be too busy with his new role as Executive Chairman at Pharmaust... perhaps CZD pay more in directors fees than IDT (probably not hard!)
The Pharmaust mentioned his time at Mayne Pharma and Neurodiscovery (to which he was appointed in Feb). However the NDL announcement gave a more complete bio:
"Dr Roger Aston is currently the CEO of Pitney Pharmaceuticals Ltd, chairman of BioLife Ltd, director of Immuron Ltd, director of IDT Ltd, Director of Regeneus Ltd and Cynata Ltd. He holds a B.Sc. (Hons) and Ph.D. degrees at the University of Manchester (1975-1981) and worked previously at the Wellcome Foundation now Glaxo SmithKline. Since 1981 Mr Aston has worked with Peptech, Cambridge Antibody Technology, Cambridge Drug Discovery, QinetiQ, Clinuvel, pSiMedica, pSivida, Halcygen, Ascent Pharma Health and his last position was CEO of Mayne Pharma Group."
CZD Price at posting:
7.7¢ Sentiment: LT Buy Disclosure: Not Held
